EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1

Gregory Parsonage, Kevin Cuthbertson, Naima Endesh, Nicoletta Murciano, Adam J Hyman, Charlotte H Revill, Oleksandr V Povstyan, Eulashini Chuntharpursat-Bon iD, Marjolaine Debant, Melanie J Ludlow, Timothy Simon Futers, Laeticia Lichtenstein und 7 weitere

British Journal of Pharmacology · 2023-08 · 180 (16) · 2039-2063

DOI: 10.1111/bph.15996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 31.01.2023. Verfasst von Gregory Parsonage und 18 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Calcium, Mechanotransduction, Cellular. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Biotechnology and Biological Sciences Research Council, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose The protein PIEZO1 forms mechanically activated, calcium‐permeable, non‐selective cation channels in numerous cell types from several species. Options for pharmacological modulation are limited and so we modified a small‐molecule agonist at PIEZO1 channels (Yoda1) to increase the ability to modulate these channels. Experimental Approach Medicinal chemistry generated Yoda1 analogues that were tested in intracellular calcium and patch‐clamp assays on cultured cells exogenously expressing human or mouse PIEZO1 or mouse PIEZO2. Physicochemical assays and wire myography assays on veins from mice with genetic disruption of PIEZO1. Key Results A Yoda1 analogue (KC159) containing 4‐benzoic acid instead of the pyrazine of Yoda1 and its potassium salt (KC289) have equivalent or improved reliability, efficacy and potency, compared with Yoda1 in functional assays. Tested against overexpressed mouse PIEZO1 in calcium assays, the order of potency (as EC 50 values, nM) was KC289, 150 > KC159 280 > Yoda1, 600). These compounds were selective for PIEZO1 over other membrane proteins, and the physicochemical properties were more suited to physiological conditions than those of Yoda1. The vasorelaxant effects were consistent with PIEZO1 agonism. In contrast, substitution with 2‐benzoic acid failed to generate a modulator. Conclusion and Implications 4‐Benzoic acid modification of Yoda1 improves PIEZO1 agonist activity at PIEZO1 channels. We suggest naming this new modulator Yoda2. It should be a useful tool compound in physiological assays and facilitate efforts to identify a binding site. Such compounds may have therapeutic potential, for example, in diseases linked genetically to PIEZO1 such as lymphatic dysplasia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalciumMechanotransduction, CellularMiceHumansAnimalsReproducibility of ResultsBinding SitesCalcium ChannelsIon Channels

Stichwörter der Autor:innen

calcium channelendothelial cellmechanical forcemedicinal chemistrynon-selective cation channelpharmacologyvascular biology

Substanzen

CalciumCalcium ChannelsPIEZO1 protein, humanIon Channels

Autor:innen und Institutionen

  • Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, UK.
  • School of Chemistry, University of Leeds, Leeds, UK.
  • Nanion Technologies GmbH, Munich, Germany.
  • Theoretical Medicine and Biosciences, Saarland University, Homburg, Germany.

ORCID-Profile: Eulashini Chuntharpursat-Bon, David J Beech

Förderung

  • Wellcome Trust
  • Biotechnology and Biological Sciences Research Council
  • British Heart Foundation
  • University of Leeds

Zitieren

APA

Parsonage, G., Cuthbertson, K., Endesh, N., Murciano, N., Hyman, A. J., Revill, C. H., Povstyan, O. V., Chuntharpursat-Bon, E., Debant, M., Ludlow, M. J., Futers, T. S., Lichtenstein, L., Kinsella, J. A., Bartoli, F., Rotordam, M. G., Becker, N., Brüggemann, A., Foster, R., & Beech, D. J. (2023). Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1. British Journal of Pharmacology, 180(16), 2039-2063. https://doi.org/10.1111/bph.15996

Vancouver

Parsonage G, Cuthbertson K, Endesh N, Murciano N, Hyman AJ, Revill CH, et al. Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1. British Journal of Pharmacology. 2023;180(16):2039-2063. doi:10.1111/bph.15996

BibTeX
@article{Parsonage2023,
  author = {Parsonage, Gregory and Cuthbertson, Kevin and Endesh, Naima and Murciano, Nicoletta and Hyman, Adam J and Revill, Charlotte H and Povstyan, Oleksandr V and Chuntharpursat-Bon, Eulashini and Debant, Marjolaine and Ludlow, Melanie J and Futers, Timothy Simon and Lichtenstein, Laeticia and Kinsella, Jacob A and Bartoli, Fiona and Rotordam, Maria Giustina and Becker, Nadine and Brüggemann, Andrea and Foster, Richard and Beech, David J},
  title = {Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1},
  journal = {British Journal of Pharmacology},
  year = {2023},
  volume = {180},
  number = {16},
  pages = {2039--2063},
  doi = {10.1111/bph.15996}
}
Kostenlos starten →